tumor mutational burden
Diagnostics Firms, Lab Providers Form Genomic Profiling Coalition
The new consortium is aiming to make comprehensive genomic profiling accessible to advanced cancer patients in the US, to help inform their treatment decisions.
FDA Approves Foundation Medicine Liquid Biopsy Test as CDx for Lynparza
The test will use a blood-based biopsy to detect patients with BRCA1, BRCA2, and/or ATM alterations in metastatic castration-resistant prostate cancer.
TMB Harmonization Effort Yields Calibration Method to Correct Inter-Assay Variation
A consortium convened by Friends of Cancer Research has made progress in quantifying sources of TMB assay discordance and created a new test-alignment software tool.
NCCN's Updated Inherited Colorectal Cancer Risk Guidelines Features Gene-Specific Information
The updated guidelines now also highlight the use of PCR and next-generation sequencing to determine microsatellite instability
FDA Approves Merck's Keytruda, Foundation Medicine CDx for TMB-High Solid Tumors
The accelerated approval is based on data showing that refractory cancer patients with TMB of at least 10 mutations/Mb saw tumor shrinkage and had durable responses on the immunotherapy.